Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials


Por: Ferrarotto R, Anderson I, Medgyasszay B, Garcia-Campelo M, Edenfield W, Feinstein T, Johnson J, Kalmadi S, Lammers P, Sanchez-Hernandez A, Pritchett Y, Morris S, Malik R, Csoszi T

Publicada: 1 sep 2021 Ahead of Print: 1 ago 2021
Resumen:
Background Supportive care interventions used to manage chemotherapy-induced myelosuppression (CIM), including granulocyte colony-stimulating factors (G-CSFs), erythropoiesis-stimulating agents (ESAs), and red blood cell (RBC) transfusions, are burdensome to patients and associated with greater costs to health care systems. We evaluated the utilization of supportive care interventions and their relationship with the myeloprotective agent, trilaciclib. Methods Data were pooled from three independent randomized phase 2 clinical trials of trilaciclib or placebo administered prior to chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). The impact of supportive care on the duration of severe neutropenia (DSN), occurrence of severe neutropenia (SN), and occurrence of RBC transfusions on/after week 5 was analyzed across cycles 1-4. Concordance and association between grade 3/4 anemia, RBC transfusions on/after week 5, and ESA administration was also evaluated. Results The use of G-CSFs, ESAs, or RBC transfusions on/after week 5 was significantly lower among patients receiving trilaciclib versus placebo (28.5% vs. 56.3%, p < 0.0001; 3.3% vs. 11.8%, p = 0.0254; and 14.6% vs. 26.1%, p = 0.0252, respectively). Compared with placebo, trilaciclib significantly reduced DSN and SN, irrespective of G-CSF administration. RBC transfusions and ESAs were most often administered in patients with grade 3/4 anemia; however, patients typically received RBC transfusions over ESA administration. Conclusions By improving CIM and reducing the need for associated supportive care, trilaciclib has the potential to reduce the burden of myelosuppression on patients receiving myelosuppressive chemotherapy for the treatment of ES-SCLC. Trial registration ClinicalTrials.gov (NCT02499770; NCT03041311; NCT02514447).

Filiaciones:
Ferrarotto R:
 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

Anderson I:
 St Joseph Heritage Healthcare, Santa Rosa, CA USA

Medgyasszay B:
 Veszprem Cty Lung Med Inst, Veszprem, Hungary

Garcia-Campelo M:
 Univ Hosp A Coruna, La Coruna, Spain

Edenfield W:
 Prisma Hlth Canc Inst, Greenville, SC USA

Feinstein T:
 Piedmont Canc Inst, Atlanta, GA USA

 Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA

Kalmadi S:
 Ironwood Canc & Res Ctr, Chandler, AZ USA

Lammers P:
 Baptist Canc Ctr, Memphis, TN USA

Sanchez-Hernandez A:
 Hosp Prov Castellon, Castellon de La Plana, Spain

Pritchett Y:
 G1 Therapeut Inc, Res Triangle Pk, NC USA

Morris S:
 G1 Therapeut Inc, Res Triangle Pk, NC USA

 Istari Oncol, Morrisville, NC USA

Malik R:
 G1 Therapeut Inc, Res Triangle Pk, NC USA

Csoszi T:
 Hetenyi Geza Korhaz, Szolnok, Hungary
ISSN: 20457634





Cancer Medicine
Editorial
John Wiley and Sons Ltd, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Estados Unidos America
Tipo de documento: Article
Volumen: 10 Número: 17
Páginas: 5748-5756
WOS Id: 000686455000001
ID de PubMed: 34405547
imagen Green Published, gold

MÉTRICAS